India’s first HPV vaccine against cervical cancer: everything you need to know


The Department of Biotechnology (DBT) on Thursday announced the scientific completion of India’s first locally produced quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer.

The vaccine against cervical cancer, the quadrivalent human papillomavirus (qHPV) vaccine, is being developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).

according to dr COVID Working Group Chair NK Arora told the National Technical Advisory Group on Immunization (NTAGI) it is an exciting experience to bring an Indian-made vaccine to market.

“It is very exciting and I must say it makes us very happy that our daughters and granddaughters can now receive this long-awaited vaccine.”

“In fact, this is one of the last major vaccines to be rolled out. In fact, this is one of the last vaccines to be introduced in the program. Now Indian vaccines will be available and we hope they will be introduced in the national vaccination program for 9-14 year old girls,” he added.

“It is very effective and it prevents cervical cancer because 85% to 90% of the time cervical cancer is due to this particular virus and this vaccine is against these viruses. So if we give it to our young children and daughters, they are protected from infection and consequently cancer is unlikely to occur 30 years later,” continued Dr Arora.

“There was a shortage on the world market. Now the Indian vaccine has come. So we will be able to meet our needs within our Indian-made vaccine,” he said.

According to the World Health Organization (WHO), 41,91,000 women have died from cervical cancer in India since 2019.

What is cervical cancer?

When cancer starts in the cervix, it is called cervical cancer. According to the Centers for Disease Control and Prevention, all women are at risk of cervical cancer. It occurs most commonly in women over the age of 30. Long-term infection with certain types of human papillomavirus (HPV) is the leading cause of cervical cancer. If cervical cancer is caught early, it is highly treatable and associated with long survival and a good quality of life.

HPV vaccine

The HPV vaccine protects against the types of HPV that most commonly cause cervical, vaginal and vulvar cancer. India was completely dependent on foreign manufacturers for the HPV vaccine. However, on September 1st, India will receive its first home-developed qHPV vaccine.

The Serum Institute’s qHPV vaccine received marketing approval from the Drugs Controller General of India (DCGI) on July 12.

Get all the business news, market news, breaking news and latest news updates on Live Mint. Download the Mint News app for daily market updates.

More less

Subscribe to something Mint newsletter

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Post your comment


Comments are closed.